Literature DB >> 19426223

Immune regulation by 4-1BB and 4-1BBL: complexities and challenges.

Chao Wang1, Gloria H Y Lin, Ann J McPherson, Tania H Watts.   

Abstract

SUMMARY: The tumor necrosis factor receptor family member 4-1BB plays a key role in the survival of activated and memory CD8(+) T cells. Depending on the disease model, 4-1BB can participate at different stages and influence different aspects of the immune response, likely due to the differential expression of receptor and ligand relative to other costimulatory molecules. Studies comparing mild versus severe influenza infection of mice suggest that the immune system uses inducible receptors such as 4-1BB to prolong the immune response when pathogens take longer to clear. The expression of 4-1BB on diverse cell types, evidence for bidirectional as well as receptor-independent signaling by 4-1BBL, the unexpected hyperproliferation of 4-1BB-deficient T cells, and complex effects of agonistic anti-4-1BB therapy have revealed additional roles for the 4-1BB/4-1BBL receptor/ligand pair in the immune system. In this review, we discuss these diverse roles of 4-1BB and its ligand in the immune response, exploring possible mechanisms for the observed complexities and implications for therapeutic applications of 4-1BB/4-1BBL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19426223     DOI: 10.1111/j.1600-065X.2009.00765.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  129 in total

Review 1.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

Review 2.  Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets.

Authors:  Alison M Gizinski; David A Fox; Sujata Sarkar
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-08       Impact factor: 4.098

Review 3.  Potential importance of B cells in aging and aging-associated neurodegenerative diseases.

Authors:  Arya Biragyn; Maria Aliseychik; Evgeny Rogaev
Journal:  Semin Immunopathol       Date:  2017-01-12       Impact factor: 9.623

4.  Cross-linking of CD137 ligand modulates immune responses of thioglycollate-elicited mouse peritoneal macrophages.

Authors:  Jun-Sang Bae; Hyeong-Sup Kim; Jae Hong Park; Sang-Hyuk Park; Hyeon-Woo Lee
Journal:  Inflamm Res       Date:  2010-12-24       Impact factor: 4.575

5.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

6.  The CD137 Ligand Is Important for Type 1 Diabetes Development but Dispensable for the Homeostasis of Disease-Suppressive CD137+ FOXP3+ Regulatory CD4 T Cells.

Authors:  Bardees M Foda; Ashley E Ciecko; David V Serreze; William M Ridgway; Aron M Geurts; Yi-Guang Chen
Journal:  J Immunol       Date:  2020-04-15       Impact factor: 5.422

7.  Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice.

Authors:  Sujin Lee; Robert S Mittler; Martin L Moore
Journal:  J Immunol       Date:  2013-11-27       Impact factor: 5.422

Review 8.  Suboptimal engagement of the T-cell receptor by a variety of peptide-MHC ligands triggers T-cell anergy.

Authors:  Scheherazade Sadegh-Nasseri; Sarat K Dalai; Laura C Korb Ferris; Saied Mirshahidi
Journal:  Immunology       Date:  2009-12-02       Impact factor: 7.397

9.  Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.

Authors:  Brett Schrand; Alexey Berezhnoy; Randall Brenneman; Anthony Williams; Agata Levay; Ling-Yuan Kong; Ganesh Rao; Shouhao Zhou; Amy B Heimberger; Eli Gilboa
Journal:  Cancer Immunol Res       Date:  2014-06-17       Impact factor: 11.151

10.  Therapeutic vaccination with 4-1BB co-stimulation eradicates mouse acute myeloid leukemia.

Authors:  Daniel Kerage; Megan S F Soon; Brianna L Doff; Takumi Kobayashi; Michael D Nissen; Pui Yeng Lam; Graham R Leggatt; Stephen R Mattarollo
Journal:  Oncoimmunology       Date:  2018-07-26       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.